|Bid||120.04 x 800|
|Ask||120.09 x 3100|
|Day's Range||119.20 - 126.71|
|52 Week Range||72.14 - 136.26|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||57.38|
|Earnings Date||Nov 02, 2020 - Nov 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 29, 1995|
|1y Target Est||135.40|
NBIX earnings call for the period ending June 30, 2020.
This article will reflect on the compensation paid to Kevin Gorman who has served as CEO of Neurocrine Biosciences...
Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. Here's what you need to know about Neurocrine's impressive Q2 update. Neurocrine reported revenue of $302.4 million in the second quarter, a 65% increase from the $183.5 million reported in the prior-year period.